🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
4.080
+0.160 (4.08%)
At close: Nov 19, 2026, 4:00 PM EST
4.130
+0.050 (1.23%)
After-hours: Nov 19, 2026, 7:51 PM EST

Opus Genetics Statistics

Total Valuation

Opus Genetics has a market cap or net worth of $394.35 million. The enterprise value is $341.26 million.

Market Cap394.35M
Enterprise Value 341.26M

Important Dates

The last earnings date was Tuesday, November 10, 2026, before market open.

Earnings Date Nov 10, 2026
Ex-Dividend Date n/a

Share Statistics

Opus Genetics has 96.65 million shares outstanding. The number of shares has increased by 83.71% in one year.

Current Share Class 96.65M
Shares Outstanding 96.65M
Shares Change (YoY) +83.71%
Shares Change (QoQ) -8.57%
Owned by Insiders (%) 16.61%
Owned by Institutions (%) 66.67%
Float 53.28M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 49.83
Forward PS 32.22
PB Ratio 10.17
P/TBV Ratio 10.26
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 43.12
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 9.65, with a Debt / Equity ratio of 0.93.

Current Ratio 9.65
Quick Ratio 9.39
Debt / Equity 0.93
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -39.30

Financial Efficiency

Return on equity (ROE) is -615.57% and return on invested capital (ROIC) is -94.57%.

Return on Equity (ROE) -615.57%
Return on Assets (ROA) -58.54%
Return on Invested Capital (ROIC) -94.57%
Return on Capital Employed (ROCE) -72.01%
Weighted Average Cost of Capital (WACC) 8.24%
Revenue Per Employee $282,643
Profits Per Employee -$4.88M
Employee Count28
Asset Turnover 0.12
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +117.02% in the last 52 weeks. The beta is 0.80, so Opus Genetics's price volatility has been lower than the market average.

Beta (5Y) 0.80
52-Week Price Change +117.02%
50-Day Moving Average 4.39
200-Day Moving Average 4.30
Relative Strength Index (RSI) 50.23
Average Volume (20 Days) 1,037,513

Short Selling Information

The latest short interest is 10.86 million, so 11.24% of the outstanding shares have been sold short.

Short Interest 10.86M
Short Previous Month 13.34M
Short % of Shares Out 11.24%
Short % of Float 20.39%
Short Ratio (days to cover) 6.72

Income Statement

In the last 12 months, Opus Genetics had revenue of $7.91 million and -$136.65 million in losses. Loss per share was -$1.50.

Revenue7.91M
Gross Profit -38.79M
Operating Income -61.54M
Pretax Income -136.65M
Net Income -136.65M
EBITDA -61.48M
EBIT -61.54M
Loss Per Share -$1.50
Full Income Statement

Balance Sheet

The company has $88.97 million in cash and $35.88 million in debt, with a net cash position of $53.09 million or $0.55 per share.

Cash & Cash Equivalents 88.97M
Total Debt 35.88M
Net Cash 53.09M
Net Cash Per Share $0.55
Equity (Book Value) 38.43M
Book Value Per Share 0.40
Working Capital 85.02M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$48.55 million and capital expenditures -$189,000, giving a free cash flow of -$48.74 million.

Operating Cash Flow -48.55M
Capital Expenditures -189,000
Depreciation & Amortization 62,000
Net Borrowing 35.00M
Free Cash Flow -48.74M
FCF Per Share -$0.50
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin -777.66%
Pretax Margin -1,726.70%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Opus Genetics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -83.71%
Shareholder Yield -83.71%
Earnings Yield -36.71%
FCF Yield -12.36%

Analyst Forecast

The average price target for Opus Genetics is $13.94, which is 241.67% higher than the current price. The consensus rating is "Strong Buy".

Price Target $13.94
Price Target Difference 241.67%
Analyst Consensus Strong Buy
Analyst Count 17
Revenue Growth Forecast (3Y) 45.80%
EPS Growth Forecast (3Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a
Graham Formula Value n/a
Graham Formula Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Opus Genetics has an Altman Z-Score of -2.67 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -2.67
Piotroski F-Score 2